Mind Medicine Completes Pre-IND Meeting For LSD Assisted Therapy In Anxiety

Mind Medicine (NEO: MMED) this morning issued a brief update related two products within its research pipeline. Firstly, the company has completed a meeting with the US Food and Drug Administration in relation to its LSD assisted therapy for anxiety. And secondly, Mindmed has completed analyzing preliminary data for its 18-MC phase 1 clinical study.

In terms of its LSD assisted therapy for the treatment of anxiety, the company has concluded its pre-investigational new drug meeting with the FDA. The meeting was said to be a success, with the company indicating that it intends to file an application for a new IND with the agency in August 2021. If approved, the IND would see the company conducted a phase 2b clinical trial to evaluate the use of LSD against anxiety.

Speaking to Project Layla, which is Mind Medicine’s ibogaine-derived formulation known as 18-MC, the company is said to have completed analysis of preliminary data for the planned addiction treatment program. Both the Single Ascending Dose study as well as the Multiple Ascending Dose study have reportedly demonstrated that the drug is safe and well tolerated at the current dosages test, with no serious adverse effects.

Dose escalation is as a result expected to continue for the 18-MC trials, and upon additional data being reviewed, the company will look to initiate a Phase 2a proof of concept study. The company has indicated that a meeting with the FDA has been confirmed to discuss the development of the drug.

Mind Medicine last traded at $4.57 on the Neo Exchange.


Information for this briefing was found via Sedar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Mind Medicine CFO Quits Ahead Of Release Of 2021 Financial Results

It’s always a positive sign when a chief financial officer resigns the last business day...

Monday, March 28, 2022, 06:45:00 AM

Mind Medicine Applies To List On The Nasdaq

Mind Medicine (NEO: MMED) this morning announced that it has submitted an application to uplist...

Monday, September 21, 2020, 07:53:31 AM

Mind Medicine: Canaccord Genuity Initiates Coverage With C$1.75 Price Target

Yesterday, Canaccord initiated coverage on Mind Medicine (NEO: MMED) with a Speculative Buy rating and...

Wednesday, September 16, 2020, 04:15:00 PM

Mind Medicine Prices $30 Million Offering At 30% Discount To Market

Mind Medicine (NEO: MMED) has elected to destroy shareholder value in a major way this...

Wednesday, September 28, 2022, 09:28:04 AM

MindMed Launches Psychedelic-Based Pain Treatment Project

Mind Medicine Inc. (NEO: MMED), also known as MindMed, announced today that it has launched...

Wednesday, May 5, 2021, 09:44:00 AM